Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
基本信息
- 批准号:10326954
- 负责人:
- 金额:$ 50.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-06-15 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAntiviral AgentsBindingBiochemicalBiophysicsCD4 Positive T LymphocytesCapsid ProteinsCell Cycle ArrestClassificationCommunitiesComparative StudyComplexCryoelectron MicroscopyCyclophilin ACytidine DeaminaseDeaminationDegradation PathwayEvolutionFluorescenceGoalsHIVHIV-1Host Defense MechanismHuman Parainfluenza Virus 2ImmuneImmune systemIn VitroInfectionIntegration Host FactorsKnowledgeMammalsMediatingMethodsMolecularMutagenesisPPP2R5A genePathway interactionsPeptidylprolyl IsomerasePrimate LentivirusesProtein FamilyProtein IsoformsProtein phosphataseProteinsResearchResearch DesignResearch Project GrantsResolutionReverse TranscriptionSheepSpectrum AnalysisStructureSystemTechniquesTherapeuticTranscriptUbiquitinValidationViralViral PhysiologyViral ProteinsVirionVirus DiseasesVirus ReplicationVisna-maedi virusWorkX-Ray Crystallographycellular targetingcofactorcombatdesignexperimental studyfactor Ain vivoinhibitor/antagonistinsightmulticatalytic endopeptidase complexnovel therapeuticspathogenprotein degradationreconstructionrecruitstructural biologythree dimensional structuretooltranscription factorubiquitin-protein ligase
项目摘要
PROJECT DESCRIPTION
The APOBEC3 (A3) family of proteins are cellular cytidine deaminases that suppress human
immunodeficiency virus type 1 (HIV-1) infection by hypermutation of viral reverse transcripts and physically
blocking reverse transcription. To evade this host defense mechanism, HIV-1 expresses the virion infectivity
factor (Vif), which hijacks a cellular E3 ubiquitin ligase complex and targets A3 proteins (A3F/G/H/D) for
proteasome-mediated degradation. Besides degrading A3s, HIV-1 Vif also causes G2 cell cycle arrest by
targeting multiple protein phosphatase 2A (PP2A) regulators (PPP2R5 proteins) for degradation. Adding to the
complexity of Vif-host protein interactions, HIV-1 Vif utilizes the transcription factor CBFβ as a non-canonical
cofactor, while maedi-visna virus (MVV) Vif co-opts the prolyl isomerase cyclophilin A (CypA) instead. Our goal
is to establish the biochemical and structural principles for the multifaceted activities of lentiviral Vif molecules
that recruit cellular factors to degrade host proteins via ubiquitin-proteasome pathways. To achieve our goal,
we will use a combination of biochemical, biophysical, structural biology, and cellular functional techniques. To
establish the mechanisms by which A3 proteins are targeted by the HIV-1 Vif (Aim1), we will determine high-
resolution structures of the A3-Vif-E3 interaction complexes, validate these structures by structure-guided
mutagenesis experiments in vitro and in vivo, and interrogate the molecular determinants of Vif/A3/E3 ligase
assembly and activation. In addition, we will also study the degradation-independent mode of Vif inhibition of
A3 deamination and antiviral activities. To better understand CypA-mediated formation of MVV Vif-E3 ubiquitin
ligase (Aim2), we will assemble MVV Vif/CypA/E3 ligase complexes with or without A3 substrates, determine
their high-resolution structures, and perform biochemical and functional validations of our structural
observations. The influences of capsid proteins on the assembly and activation of MVV Vif-E3 ligase will also
be investigated. To delineate the mechanisms of PPP2R5/PP2A recruitment by lentiviral Vif-E3 ubiquitin
ligases (Aim3), we will investigate the effects of PPP2R5 proteins on the assemblies of the CBFβ-mediated
HIV-1 Vif and CypA-mediated MVV Vif-E3 ligases, obtain high-resolution structures, and perform structure-
guided validations. Our comprehensive research design provides a robust approach that will generate
unprecedented insights into the diverse functions of lentiviral Vif molecules.
项目描述
APOBEC 3(A3)蛋白家族是细胞胞苷脱氨酶,其抑制人类免疫应答。
免疫缺陷病毒1型(HIV-1)感染通过病毒逆转录和物理
阻断逆转录。为了逃避这种宿主防御机制,HIV-1表达了病毒粒子的感染性,
因子(Vif),其劫持细胞E3泛素连接酶复合物并靶向A3蛋白(A3 F/G/H/D),
蛋白酶体介导的降解。除了降解A3,HIV-1 Vif还通过以下方式引起G2细胞周期阻滞:
靶向多种蛋白磷酸酶2A(PP 2A)调节剂(PPP 2 R5蛋白)进行降解。增加了
由于Vif与宿主蛋白质相互作用的复杂性,HIV-1 Vif利用转录因子CBFβ作为非经典转录因子。
辅因子,而梅迪-维斯纳病毒(MVV)Vif替代脯氨酰异构酶亲环素A(CypA)。我们的目标
是建立慢病毒Vif分子多方面活动的生物化学和结构原理
通过泛素-蛋白酶体途径募集细胞因子降解宿主蛋白质。为了实现我们的目标,
我们将结合使用生物化学、生物物理学、结构生物学和细胞功能技术。到
建立A3蛋白被HIV-1 Vif(Aim 1)靶向的机制,我们将确定高水平的
A3-Vif-E3相互作用复合物的解析结构,通过结构引导的
体外和体内诱变实验,并询问Vif/A3/E3连接酶的分子决定簇
组装和激活。此外,我们还将研究Vif抑制的非降解依赖模式,
A3脱氨基和抗病毒活性。为了更好地理解CypA介导的MVV Vif-E3泛素形成
连接酶(Aim 2),我们将组装MVV Vif/CypA/E3连接酶复合物,有或没有A3底物,确定
他们的高分辨率结构,并执行生化和功能验证我们的结构
意见。本文还研究了衣壳蛋白对MVV Vif-E3连接酶组装和活化的影响。
追究描述慢病毒Vif-E3泛素募集PPP 2 R5/PP 2A的机制
连接酶(Aim 3),我们将研究PPP 2 R5蛋白对CBFβ介导的
HIV-1 Vif和CypA介导的MVV Vif-E3连接酶,获得高分辨率结构,并进行结构-
引导验证。我们全面的研究设计提供了一个强大的方法,将产生
这是对慢病毒Vif分子的多种功能的前所未有的了解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Yong Xiong其他文献
Yong Xiong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Yong Xiong', 18)}}的其他基金
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
- 批准号:
10640135 - 财政年份:2015
- 资助金额:
$ 50.25万 - 项目类别:
Recognition of Viral DNA by APOBEC3 Proteins and their Antagonization by HIV Vif
APOBEC3 蛋白对病毒 DNA 的识别及其 HIV Vif 的拮抗作用
- 批准号:
8992425 - 财政年份:2015
- 资助金额:
$ 50.25万 - 项目类别:
Recognition of Viral DNA by APOBEC3 Proteins and their Antagonization by HIV Vif
APOBEC3 蛋白对病毒 DNA 的识别及其 HIV Vif 的拮抗作用
- 批准号:
9079350 - 财政年份:2015
- 资助金额:
$ 50.25万 - 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
- 批准号:
10600207 - 财政年份:2015
- 资助金额:
$ 50.25万 - 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
- 批准号:
10774368 - 财政年份:2015
- 资助金额:
$ 50.25万 - 项目类别:
Multifaceted interactions between lentiviral Vif and host molecules for viral infectivity enhancement
慢病毒 Vif 与宿主分子之间的多方面相互作用增强病毒感染力
- 批准号:
10414141 - 财政年份:2015
- 资助金额:
$ 50.25万 - 项目类别:
Mechanisms of enveloped virus tethering by tetherin and viral countermeasures
系链蛋白束缚包膜病毒的机制和病毒对策
- 批准号:
8824868 - 财政年份:2011
- 资助金额:
$ 50.25万 - 项目类别:
Mechanisms of enveloped virus tethering by tetherin and viral countermeasures
系链蛋白束缚包膜病毒的机制和病毒对策
- 批准号:
8467997 - 财政年份:2011
- 资助金额:
$ 50.25万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 50.25万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 50.25万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 50.25万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 50.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 50.25万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 50.25万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 50.25万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 50.25万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 50.25万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 50.25万 - 项目类别:














{{item.name}}会员




